DENVER, April 28 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG), a
biopharmaceutical company focused on the discovery, development and
commercialization of small molecule therapeutics for the treatment of
cardiovascular disorders, today announced that Joseph L. Turner, Chief
Financial Officer, will present a corporate overview at the Needham & Company
Biotechnology Conference.
The presentation will take place at 8:00 a.m. (Eastern) on Thursday,
May 26, 2005. There will be a live webcast of the presentation, which will be
accessible through a link posted on the investor relations section of the
Myogen website at http://investor.myogen.com/. The webcast will be available
for replay on Myogen's website through June 10, 2005.
Myogen currently markets one product (Perfan(R) I.V.) in Europe for the
treatment of acute decompensated heart failure and has three product
candidates in late-stage clinical development: enoximone capsules for the
treatment of patients with advanced chronic heart failure, ambrisentan for the
treatment of patients with pulmonary arterial hypertension (PAH) and
darusentan for the treatment of patients with resistant systolic hypertension.
The company, in collaboration with Novartis, also conducts a target and drug
discovery research program focused on the development of disease-modifying
drugs for the treatment of chronic heart failure and related cardiovascular
disorders. Please visit our website at http://www.myogen.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements that
involve significant risks and uncertainties, including those to be discussed
in the presentation and others that can be found in the "Risk Factors" section
of Myogen's Form 10-K for the year ended December 31, 2004 and Myogen's
periodic reports on Form 10-Q and Form 8-K. Myogen does not undertake any
obligation to update any forward-looking statements contained in the
anticipated presentation as a result of new information, future events or
otherwise. The company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release or the
presentation. No forward-looking statement can be guaranteed and actual
events and results may differ materially from those projected.
SOURCE Myogen, Inc.
 back to top
Related links:
http://www.myogen.com
CONTACT:
Derek K. Cole, Director, Investor Relations
of Myogen, +1-303-464-3986, derek.cole@myogen.com
|
